Vetoquinol

2021 Annual Results - Seite 3

The Vetoquinol laboratory continues to rigorously manage the health situation related to Covid-19 and works to guarantee the safety and health of its employees, while aiming to develop industrial activity, the Group's projects and the quality of service to its customers.

Next update: Q1 2022 sales, April 13^th, 2022 after market close

ABOUT VETOQUINOL
Vetoquinol is a leading global animal health company that supplies drugs and non-medicinal products for the livestock (cattle and pigs) and pet (dogs and cats) markets.
As an independent pure player, Vetoquinol designs, develops and sells veterinary drugs and non-medicinal products in Europe, the Americas and the Asia Pacific region.
Since its foundation in 1933, Vetoquinol has pursued a strategy combining innovation with geographical diversification. The Group’s hybrid growth is driven by the reinforcement of its product portfolio coupled with acquisitions in high potential growth markets.
Vetoquinol employed 2,546 people as of December 31^th, 2021.
Vetoquinol has been listed on Euronext Paris since 2006 (symbol: VETO).
The Vetoquinol share is eligible for the French PEA and PEA-PME personal equity plans.

ANNEX

SALES

€m	2021	2020	Change (reported data)	Change (constant exchange rates)	Organic growth
Q1 sales	127.9	103.4	+23.8%	+28.3%	+11.7%
Q2 sales	127.4	92.7	+37.3%	+39.2%	+23.8%
Q3 sales	132.3	114.4	+15.7%	+14.3%	+10.0%
Q4 sales	133.7	117.0	+14.3%	+11.3%	+11.3%
Annual sales